Format

Send to

Choose Destination
Expert Opin Investig Drugs. 2011 Jan;20(1):107-17. doi: 10.1517/13543784.2011.542148. Epub 2010 Dec 11.

Patupilone in cancer treatment.

Author information

1
Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey, SM2 5PT, UK. ian.chau@rmh.nhs.uk

Abstract

IMPORTANCE OF THE FIELD:

Since the introduction of taxane-based chemotherapy for advanced solid tumors in the 1990s, the median overall survival of patients with metastatic breast cancer increased from 2 years to almost 5 years. Similarly, the 5-year overall survival for ovarian cancer has increased from 30% to more than 40%.

AREAS COVERED IN THIS REVIEW:

Patupilone is a novel cytotoxic compound, with similar microtubule-binding and apoptotic properties of taxanes and is active in taxane-resistant cell lines. Over 1200 patients have been treated with patupilone in Phase I - III clinical trials and a wealth of knowledge has accumulated about this compound. This review discusses current pharmacology and data from clinical trials with patupilone from the last seven years.

WHAT THE READER WILL GAIN:

We present a comprehensive summary of data from Phase II and III trials, as well as an overview of currently accruing trials.

TAKE HOME MESSAGE:

Although patupilone has not demonstrated superiority over pegylated liposomal doxorubicin in a large Phase III trial in relapsed or refractory ovarian cancer, its evaluation is continuing in a range of other malignancies, especially in primary or secondary tumors of the CNS.

PMID:
21142807
DOI:
10.1517/13543784.2011.542148
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center